Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RANT-GC Trial
NCT05733689Phase 1Recruiting
- Sponsor
- University of California, Irvine
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluorouracil, folinic acid, oxaliplatin, docetaxel, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and 6 more in gastroesophageal adenocarcinoma and gastric adenocarcinoma, sponsored by University of California, Irvine. Primary endpoint: Percentage of completing per protocol treatment at 3 years. Started Jun 2025; status: recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatindocetaxelirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
gastroesophageal adenocarcinomagastric adenocarcinoma
Beyond the preview
Go deeper on NCT05733689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05733689.